Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial

BACKGROUND: The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular eject...

Descripción completa

Detalles Bibliográficos
Autores principales: Awoyemi, Ayodeji, Mayerhofer, Cristiane, Felix, Alex S, Hov, Johannes R, Moscavitch, Samuel D, Lappegård, Knut Tore, Hovland, Anders, Halvorsen, Sigrun, Halvorsen, Bente, Gregersen, Ida, Svardal, Asbjørn, Berge, Rolf K, Hansen, Simen H, Götz, Alexandra, Holm, Kristian, Aukrust, Pål, Åkra, Sissel, Seljeflot, Ingebjørg, Solheim, Svein, Lorenzo, Andrea, Gullestad, Lars, Trøseid, Marius, Broch, Kaspar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339250/
https://www.ncbi.nlm.nih.gov/pubmed/34329947
http://dx.doi.org/10.1016/j.ebiom.2021.103511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339250/
https://www.ncbi.nlm.nih.gov/pubmed/34329947
http://dx.doi.org/10.1016/j.ebiom.2021.103511

Ejemplares similares